Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication

The Pulse by Wharton Digital Health

Content provided by The Pulse by Wharton Digital Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Pulse by Wharton Digital Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

4y ago 58:29

MP3•Episode home

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on May 10, 2025 13:33 (23d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

In this episode, we sat down with Clara Burtenshaw, Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space

115 episodes

#Tech #Wharton Digital Health